Noventra Pharma TirReta (60mg Tirzepatide + Retatrutide Stack – Multi?Dose Pen)

TirReta 60mg by Noventra Pharma is a high-potency peptide stack combining tirzepatide and retatrutide, designed to deliver advanced metabolic support, appetite regulation, and enhanced fat loss. This formulation integrates both dual and triple incretin pathway activity, creating a multi-layered approach to weight management and energy balance. Tirzepatide acts as a dual GLP?1 and GIP receptor agonist, supporting appetite suppression, improved insulin sensitivity, and reduced gastric emptying, which leads to prolonged satiety and reduced caloric intake. Retatrutide expands on this mechanism by functioning as a triple agonist (GLP?1, GIP, and glucagon receptors), introducing an additional pathway that enhances energy expenditure and fat metabolism, making it one of the most advanced compounds currently under research for metabolic optimisation. The combination of these peptides creates a synergistic effect, targeting appetite regulation, glucose metabolism, and fat oxidation simultaneously. This multi-pathway activation is associated with greater weight loss potential, improved metabolic efficiency, and enhanced body composition outcomes compared to single or dual agonist systems alone. This formulation is typically positioned within advanced weight management protocols, particularly for individuals seeking a more aggressive or comprehensive metabolic approach. The multi-dose pen format allows for consistent and controlled administration within structured routines. Key Features: - 60mg combined tirzepatide + retatrutide formulation - Dual + triple incretin pathway activation (GLP?1, GIP, glucagon) - Supports appetite suppression and prolonged satiety - Promotes improved insulin sensitivity and glucose regulation - Enhances fat metabolism and energy expenditure - Associated with advanced body composition outcomes - Multi-dose pen for precise and consistent dosing - Designed for high-level metabolic optimisation protocols Suggested Use: Typically administered in controlled doses as part of a structured protocol. Dosing is often titrated gradually based on tolerance and individual response. Usage should be guided by a qualified healthcare provider. Storage: Refrigerate at 2–8°C. Protect from light. Do not freeze. Important Information: This product is intended for use under medical supervision only. Tirzepatide is a prescription-based compound in many regions, while retatrutide is still considered an investigational compound undergoing clinical research. Potential side effects may include nausea, gastrointestinal discomfort, fatigue, or metabolic-related symptoms. Not recommended for individuals under 18, pregnant or breastfeeding individuals, or those with certain medical conditions. Always consult a qualified healthcare provider before use.